CN1551771A - 用于治疗癌症的方法和组合物 - Google Patents

用于治疗癌症的方法和组合物 Download PDF

Info

Publication number
CN1551771A
CN1551771A CNA028157109A CN02815710A CN1551771A CN 1551771 A CN1551771 A CN 1551771A CN A028157109 A CNA028157109 A CN A028157109A CN 02815710 A CN02815710 A CN 02815710A CN 1551771 A CN1551771 A CN 1551771A
Authority
CN
China
Prior art keywords
oil
composition
clofazimine
tumor
lipid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA028157109A
Other languages
English (en)
Chinese (zh)
Inventor
D��L��Ī��˹
D·L·莫里斯
M·H·波格霍拉米
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Unisearch Ltd
Original Assignee
Unisearch Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Unisearch Ltd filed Critical Unisearch Ltd
Publication of CN1551771A publication Critical patent/CN1551771A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CNA028157109A 2001-07-17 2002-07-16 用于治疗癌症的方法和组合物 Pending CN1551771A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPR6443A AUPR644301A0 (en) 2001-07-17 2001-07-17 Method and composition for treatment of cancer
AUPR6443 2001-07-17

Publications (1)

Publication Number Publication Date
CN1551771A true CN1551771A (zh) 2004-12-01

Family

ID=3830401

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA028157109A Pending CN1551771A (zh) 2001-07-17 2002-07-16 用于治疗癌症的方法和组合物

Country Status (10)

Country Link
US (1) US20040067952A1 (enExample)
EP (1) EP1423118A4 (enExample)
JP (1) JP2004536857A (enExample)
KR (1) KR20040038984A (enExample)
CN (1) CN1551771A (enExample)
AU (1) AUPR644301A0 (enExample)
BR (1) BR0211436A (enExample)
CA (1) CA2453993A1 (enExample)
MX (1) MXPA04000518A (enExample)
WO (1) WO2003007957A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108136207A (zh) * 2015-10-06 2018-06-08 红山生物医药有限公司 用于治疗癌症的联合疗法
CN119700770A (zh) * 2025-01-09 2025-03-28 首都医科大学附属北京佑安医院 氯法齐明在制备修复肠黏膜或改善肠道菌群药物中的应用

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4763681B2 (ja) * 2004-03-05 2011-08-31 ベニテック インコーポレイテッド ＲＮＡｉ作用媒介物の同時デリバリーのためのマルチプロモーター発現カセット
EP2200613B1 (en) 2007-09-21 2018-09-05 The Johns Hopkins University Phenazine derivatives and uses thereof
KR20140051555A (ko) * 2012-10-23 2014-05-02 씨지케이바이오 주식회사 전립선암 예방 및 치료용 약학 조성물
CN103360329B (zh) * 2013-07-18 2015-11-18 中国科学院南海海洋研究所 一类吩嗪化合物及其在制备抗肿瘤药物中的应用
WO2019060409A1 (en) * 2017-09-19 2019-03-28 The Cleveland Clinic Foundation INHIBITION OF CONNEXIN 46 TO TREAT A GLIOBLASTOMA AND OTHER STATES
CN119564691A (zh) * 2024-12-13 2025-03-07 首都医科大学附属北京佑安医院 氯法齐明在制备治疗癌症的药物中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3658M (fr) * 1964-02-18 1965-11-02 Michel Marie Andre Guerbet Composition huileuse pour l'injection intravasculaire.
US4578391A (en) * 1982-01-20 1986-03-25 Yamanouchi Pharmaceutical Co., Ltd. Oily compositions of antitumor drugs
JPS6296A (ja) * 1985-03-06 1987-01-06 Sumitomo Pharmaceut Co Ltd 脂溶性白金（２）錯体
EP0280741B1 (en) * 1986-08-29 1994-12-07 Kyowa Hakko Kogyo Kabushiki Kaisha Mitomycin derivatives
ZA928419B (en) * 1991-11-29 1994-03-01 Univ Pretoria Pharmaceutical substances or compositions and their use
US5763443A (en) * 1994-04-05 1998-06-09 Universiteit Van Pretoria MDR resistance treatment and novel pharmaceutically active riminophenazines
DE69528103T2 (de) * 1994-04-05 2003-05-15 Universiteit Van Pretoria, Gauteng Verwendung von Riminophenazin zur Behandlung von MDR-Resistenz
DE19843223A1 (de) * 1998-09-22 2000-03-30 Hassan Jomaa Phosphororganische Verbindungen und ihre Verwendung
AUPP332898A0 (en) * 1998-05-04 1998-05-28 Unisearch Limited Pharmaceutical composition

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108136207A (zh) * 2015-10-06 2018-06-08 红山生物医药有限公司 用于治疗癌症的联合疗法
CN119700770A (zh) * 2025-01-09 2025-03-28 首都医科大学附属北京佑安医院 氯法齐明在制备修复肠黏膜或改善肠道菌群药物中的应用

Also Published As

Publication number Publication date
EP1423118A1 (en) 2004-06-02
JP2004536857A (ja) 2004-12-09
BR0211436A (pt) 2004-07-13
US20040067952A1 (en) 2004-04-08
EP1423118A4 (en) 2006-03-22
WO2003007957A1 (en) 2003-01-30
KR20040038984A (ko) 2004-05-08
CA2453993A1 (en) 2003-01-30
AUPR644301A0 (en) 2001-08-09
MXPA04000518A (es) 2005-03-07

Similar Documents

Publication Publication Date Title
CN1192765C (zh) 紫杉醇制剂
CN1443064A (zh) 施用含硫醇化学保护化合物的方法
US20100216755A1 (en) Anti-tumor agent
CN1674942A (zh) 氧化氮、血红素加氧酶－1和血红素降解产物的药学用途
US20250367229A1 (en) Treatment of Immune-Related Disorders, Kidney Disorders, Liver Disorders, Hemolytic Disorders, and Oxidative Stress-Associated Disorders Using NRH, NARH and Reduced Derivatives Thereof
US9101579B2 (en) Inhibition of drug resistant cancer cells
CN1441671A (zh) 用于治疗癌症的脂肪酸类似物
JP5642892B2 (ja) 多形膠芽腫の治療のためのマシテンタンを含有する組み合わせ剤
CN1551771A (zh) 用于治疗癌症的方法和组合物
Kishimoto et al. Antitumor effects of a novel lipophilic platinum complex (SM-11355) against a slowly-groing rat hepatic tumor after intra-hepatic arterial administration
JP2025015727A (ja) ｐ－ボロノフェニルアラニンを含有する注射液剤
CN1204893C (zh) 药物组合物
JP2016503035A (ja) 肝疾患または肝障害の治療のための使用および方法
WO2020053658A2 (en) Non-aqueous chemotherapeutic solutions for oral dosage
HK1070280A (en) Method and composition for treatment of cancer
Choi et al. Effect of pioglitazone on the pharmacokinetics of verapamil and its major metabolite, norverapamil, in rats
US12285412B1 (en) Organoselenium benzimidazole compounds for treating cancer
JP2022088622A5 (enExample)
WO2021049519A1 (ja) ｐ－ボロノフェニルアラニンを含有する注射液剤の析出防止方法
TWI905111B (zh) 含有對硼苯基丙胺酸之注射液劑
AU2002318983A1 (en) Mathod and composition for treatment of cancer
JPWO2016152965A1 (ja) 低アルブミン血症の改善剤
HK40067136A (zh) 含有对二羟硼基苯丙氨酸的注射液剂
CN1875944A (zh) 一种聚乙二醇修饰的羟基喜树碱隐形脂质纳米球及其制备方法
JP2004231557A (ja) エピネフリン含有抗腫瘍剤

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1070280

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1070280

Country of ref document: HK